08:00 | Registration |
|
Protein Arrays in Clinical Practice |
| |
|
Session Chair: Christer Wingren, Lund University |
| |
09:00 |  | Keynote Presentation Application of Chromosome Microarray in a Clinical Setting and Implications for Patient Management
Denise Batista, Associate Professor, Johns Hopkins University School Of Medicine, United States of America
In the clinical laboratory the use of chromosome microarray resulted in significant increase in the number of patients with a genetic diagnosis, as well as expanded the phenotypic spectrum in a variety of syndromes. It also showed that in some cases, the same genomic change can be present in patients and in controls thus implying a contribution from the genomic background and maybe environment. Clinical diagnoses achieved after microarray have direct influence on patient management.
|
|
10:00 | Coffee and Networking in Exhibition Hall |
10:45 | Reverse Phase Protein Arrays as a Tool to Identify New Biomarkers and Potential Therapeutic Targets for Breast Cancer Subtypes
Leanne De-Koning, Manager, Institut Curie, France
Reverse Phase Protein Arrays are a powerful tool to study protein expression and activation status in hundreds of samples. We applied this technology to study lobular and triple negative breast cancers with the aim to identify new prognostic biomarkers and therapeutic targets. |
11:30 | Reverse Phase Protein Array (RPPA) Applications in Translational Oncology
Ulrike Korf, Senior Scientist/Group Leader, German Cancer Research Center, Germany
New innovative, accurate, reliable and cost-effective tools are required to improve patient stratification and to bridge the gap between in vitro diagnostics and clinical decision-making. This challenge was addressed from a proteomic point-of-view, and recent data obtained by using reverse phase protein arrays (RPPA) to advance personalized medicine will be presented and discussed.
|
12:15 | Lunch & Networking in Exhibition Hall |
|
13:30 Poster Viewing | Session Sponsors |
| |
|
Session Chair: Miroslav Blumenberg, NYU Langone Medican Centre |
| |
14:15 | Functional Protein Profiling in Tissue Samples for Next Generation Molecular Diagnostics
Karl-Friedrich Becker, Head, Technical University of Munich, Germany
For functional protein profiling in clinical tissue samples it is necessary to implement tools that allow fast, precise, cheap, and simultaneous analysis of many network components while requiring only a small amount of clinical material. Reverse phase protein array (RPPA) is a promising technology that meets these requirements while enabling quantitative measurement of proteins and phosphoproteins. |
15:00 | Multi-platform Microarray Analysis for Interrogating FAK Function in Cancer
Bryan Serrels, Postdoctoral Research Scientist, University of Edinburgh, United Kingdom
We have recently identified a new and exciting role for FAK in orchestrating the composition and activation status of the tumour promoting microenvironment. Our strategy to delineate the function of nuclear FAK in cancer combines multiple microarray-based approaches, including gene expression arrays, RPPA, and antibody capture arrays. This will form the focus of my talk. |
15:45 | Coffee and Networking in Exhibition Hall |
16:30 | Molecular Profiling of Autoimmune Disease for Improved Diagnosis, Prognosis, and Classification
Christer Wingren, Associate Professor And Lecturer, Lund University, Sweden
We have shown that affinity proteomics can be used to profile crude, non-fractionated serum and urine proteomes, extracting molecular portraits of SLE and other autoimmune conditions, paving the way for improved (differential) diagnosis, prognosis, and classification based on a blood (urine) test, as well as for an enhanced understanding of the disease biology.
|
17:15 |  | Keynote Presentation Biomarkers of Clinical Relevance - How and What?
Carl Borrebaeck, Professor and Deputy Vice Chancellor, Lund University, Sweden
There is an abundance of biomarkers, although very few actually have clinical utility. Since the consensus today is that single biomarkers do not contain enough information to have any clinical relevance, we have developed a multiplexed approach resulting in accurate diagnosis of complex diseases, including cancer and autoimmunity.
|
|
18:15 | Drinks Reception |
